IDIX perhaps... but pls show me where in the the last 6 months, management said a successful interaction study means an automatic move to Phase 3 with NM283...
Also the data reported was on a treatable basis as per study design protocol and the PR stated this.
I too am disappointed that IDIX moved down... and it was because of the delay.
Idenix has a lot of positives... as you know Idenix is not paying for the trials, so they must clear all development w/ Novartis.
The trial met the endpoints for which it was designed.
Best wishes long IDIX
The creation of a thousand forests is in one acorn.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.